Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Breast Cancer
Interventions: SimpliDerm HADM, AlloDerm HADM, AlloMax HADM, FlexHD HADM, DermACELL HADM; Other
Lead sponsor: Elutia Inc.; Industry
Eligibility: Female only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Montgomery, Alabama • Muscle Shoals, Alabama • Nashville, Tennessee + 2 more

Conditions: Cancer and Chemotherapy Related Anemia
Interventions: Injectafer, Normal Saline; Drug · Other
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 29
States / cities: Corona, California • Fountain Valley, California • Riverside, California + 23 more

Conditions: Breast Cancer
Interventions: SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM; Device
Lead sponsor: Siemens Medical Solutions USA - CSG; Industry
Eligibility: 30 Years and older · Female only
Enrollment: 764 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Malvern, Pennsylvania

Conditions: Cardiomyopathy, Hypertrophic
Interventions: LCZ696, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Sarcoma, Sarcoma Metastatic
Interventions: Olaparib, Trabectedin; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cystic Fibrosis
Interventions: Salmeterol, Albuterol; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 5 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Myelogenous Leukemia
Interventions: Asciminib, Bosutinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 10
States / cities: Chicago, Illinois • Beech Grove, Indiana • Baltimore, Maryland + 6 more

Conditions: Keloid
Interventions: RXI-109, Placebo; Drug
Lead sponsor: RXi Pharmaceuticals, Corp.; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Miami, Florida • St Louis, Missouri

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Sitaxsentan, Sitaxsentan and Sildenafil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fountain Valley, California

Conditions: Chronic Subdural Hematoma, cSDH, Chronic Subdural Hematomas
Interventions: Neuro endovascular embolic coil; Device
Lead sponsor: Kaneka Medical America LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Valhalla, New York • Philadelphia, Pennsylvania

Conditions: Pressure Ulcer, Stage IV, Osteomyelitis
Interventions: STIMULAN VG, Standard of Care; Combination Product · Procedure
Lead sponsor: Biocomposites Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Phoenix, Arizona • Chicago, Illinois • Detroit, Michigan + 6 more

Conditions: GERD
Interventions: XP19986 CR, Placebo for XP19986 CR; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Stanford, California • Charleston, South Carolina • Tacoma, Washington

Conditions: Rotator Cuff Tear, Rotator Cuff Tendinitis
Interventions: Adipose Derived Regenerative Cells, Corticosteroid; Device · Drug
Lead sponsor: InGeneron, Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • La Mesa, California • Pasadena, California + 11 more

Conditions: Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions: Placebo, LX211; Drug
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more

Conditions: Cervical Dystonia
Interventions: DaxibotulinumtoxinA for injection, Placebo; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 44
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more

Conditions: Cluster Headache
Interventions: C213 Microneedle System, Placebo; Drug
Lead sponsor: Zosano Pharma Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Santa Monica, California + 9 more

Conditions: Advanced Solid Tumor
Interventions: LDE225, Wafarin, Bupropion; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 13
States / cities: Duarte, California • Kansas City, Kansas • Boston, Massachusetts + 9 more

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: treosulfan, fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation, tacrolimus, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, methotrexate; Drug · Radiation · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Denver, Colorado • Portland, Oregon • Seattle, Washington

Conditions: Obesity
Interventions: AGBS; Device
Lead sponsor: Allurion Technologies; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 14 more

Conditions: Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency
Interventions: Hectorol (doxercalciferol capsules), 0.5mcg; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 17
States / cities: Phoenix, Arizona • Alhambra, California • Riverside, California + 14 more

Conditions: Spinal Cord Injury, Quadriplegia
Interventions: NeuRx DPS; Device
Lead sponsor: Synapse Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 4
States / cities: Englewood, Colorado • Atlanta, Georgia • Cleveland, Ohio + 1 more

Conditions: Ethmoid Sinusitis, Rhinosinusitis
Interventions: AdvaCoat sinus gel, Merogel Injectable; Device
Lead sponsor: Carbylan Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 4
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 1 more

Conditions: Hairy Cell Leukemia
Interventions: Vemurafenib, Obinutuzumab, Cladribine, Rituximab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Boston, Massachusetts • Rochester, Minnesota • Basking Ridge, New Jersey + 7 more

Conditions: Prostate Cancer
Interventions: Capivasertib, Enzalutamide, Abiraterone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Indianapolis, Indiana • Omaha, Nebraska • White Plains, New York + 2 more

Search by objective public record fields.

A Retrospective Breast Reconstruction Study

Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®

Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

Prospective Multi-center Single Arm Study for Subjects With Chronic Subdural Hematoma Treated With i-ED COILs, Either Alone or in Combination With Burr-holes or Mini-craniotomy

A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Electrical Activation of The Diaphragm for Ventilatory Assist

Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer